References
- ALSUntangled [online]. Available at: http://www.alsuntangled.com/open.php. Accessed July 18, 2020.
- Drugs.com page on AZA [online]. Available at: https://www.drugs.com/monograph/AZA.html. Accessed June 24, 2020.
- UptoDate [online]. Available at: https://www.uptodate.com/contents/AZA-drug-information. Accessed June 24, 2020.
- PubChem [online]. Available at: https://pubchem.ncbi.nlm.nih.gov/compound/AZA. Accessed June 24, 2020.
- Hovden H, Frederiksen J, Pedersen S. Immune system alterations in amyotrophic lateral sclerosis. Acta Neurol Scand. 2013;128:287–96.
- Liu T, Zhang L, Joo D, Sun SC. NF-κΒ signaling in inflammation. Signal Transduct Target Ther 2017;2:17023.
- Dresselhaus EC, Meffert MK. Cellular specificity of NF-κB function in the Nervous System. Front Immunol. 2019;10:1043
- Sako W, Ito H, Yoshida M, Koizumi H, Kamada M, Fujita K, et al. Nuclear factor κB expression in patients with sporadic amyotrophic lateral sclerosis and hereditary amyotrophic lateral sclerosis with optineurin mutations. Clin Neuropathol. 2012;31:418–23.
- Frakes A, Ferraiuolo L, Haidet-Phillips A, Schmelzer L, Braun L, Miranda C, et al. Microglia induce motor neuron death via the classical NF-κB pathway in amyotrophic lateral sclerosis. Neuron 2014;81:1009–23.
- McGeer PL, McGeer EG. Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve. 2002; 26:459–70.
- Huang Y, Zhou J, Qu C, Dou Y, Huang Q, Lin Z, et. al. Anti-inflammatory effects of Brucea javanica oil emulsion by suppressing NF-κB activation on dextran sulfate sodium-induced ulcerative colitis in mice. J Ethnopharmacol. 2017;198:389–98.
- Wosiski-Kuhn M, Lyon M, Caress J, Milligan C. Inflammation, immunity, and amyotrophic lateral sclerosis: II. immune-modulating therapies. Muscle Nerve. 2019;59:23–33.
- Mora JS, Genge A, Chio A, Estol CJ, Chaverri D, Hernandez M, et al. Mastinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotroph Lat Scl FR 2020;21:5–14.
- PatientsLikeMe [online]. Available at: https://www.patientslikeme.com/treatment/AZA. Accessed July 10, 2020.
- Harrison D, Mehta P, van Es M, Stommel E, Drory V, Nefussy B, et. al. “ALS reversals”: demographics, disease characteristics, treatments, and co-morbidities. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:495–9.
- Petrou P, Argov A, Lennon VA, Gotkine M, Kassis I, Vaknin-Dembinsky A, et al. Rare combination of myasthenia and motor neuronopathy, responsive to Msc-Ntf stem cell therapy. Muscle Nerve. 2014; 49:455–7.
- Nadirakinci [online]. Available at: https://nadirakinci.com/my-als-story/. Accessed July 13, 2020.
- Kelemen J, Hedlund W, Orlin JB, Berkman EM, Munsat TL. Plasmapheresis with immunosuppression in amyotrophic lateral sclerosis. Arch Neurol. 1983;40:752–3.
- Werdelin L, Boysen G, Jensen TS, Mogensen P. Immunosuppressive treatment of patients with amyotrophic lateral sclerosis. Acta Neurol Scand. 1990;82:132–4.
- IARC Working Group on the Evaluation of Carcinogenic Risk to Humans. Pharmaceuticals. Lyon (FR): International Agency for Research on Cancer; 2012. (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, No. 100A.) AZA. Available at: https://www.ncbi.nlm.nih.gov/books/NBK304317/
- Koutsilieri S, Caudle KE, Alzghari SK, Monte AA, Relling MV, Patrinos GP. Optimizing thiopurine dosing based on TPMT and NUDT15 genotypes: it takes two to tango. Am J Hematol. 2019;94:737–40.
- Armon C. Accrued somatic mutations (nucleic acid changes) trigger ALS: 2005–2015 update. Muscle Nerve. 2016;53:842–9.
- Goldsmith P, Lennox G, Bhalla N. Azathioprine prescribing in neurology. J Neurol. 2008;255:791–5.